Clinical trial · Observational
Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Lack of funding
Summary
Brief summary (as posted)
This study targets patients with cisplatin-induced peripheral neuropathy and will allow us to: a) study peripheral neuropathy in diverse human sensory neurons in ways that were not possible previously; b) gain insight on druggable targets to treat or prevent this devastating side effect of chemotherapy; c) provide a human cellular model that can be used for screening of drugs to determine if they are neurotoxic. The combination of patient information and in vitro measurements provides a highly relevant and clinically useful model for studies aimed to impact treatment selection for the individual cancer patient.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Peripheral Nervous System Diseases | — | UNRESOLVED | — |
| Testicular Neoplasms | Testicular Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample collection | Procedure | — | UNRESOLVED |
| Report of peripheral neuropathy after cisplatin therapy | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Severe Toxicity Group
- description
- Diagnosis of testicular cancer; History of any grade 3 or higher peripheral neuropathy after receiving standard dose cisplatin completed more than 1 year but within the last 5 years; Long-term persistence (\> 6 months) of grade 2 or higher peripheral neuropathy after completion of a cisplatin containing regimen. Interventions: blood sample collection and report of peripheral neuropathy after cisplatin therapy.
- interventionNames
- Procedure: Blood sample collection
- Behavioral: Report of peripheral neuropathy after cisplatin therapy
- label
- Control Group
- description
- Diagnosis of testicular cancer; No history of neurotoxicity (grade 0-1) after completion of a standard cisplatin-containing chemotherapy regimen completed more than 1 year but within the last 5 years; Matched to a specified subject with neurotoxicity based on age (within 10 years), chemotherapy regimen or total cisplatin dosage. Interventions: blood sample collection and report of peripheral neuropathy after cisplatin therapy.
- interventionNames
- Procedure: Blood sample collection
- Behavioral: Report of peripheral neuropathy after cisplatin therapy
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria---Severe Toxicity Group 1. Diagnosis of testicular cancer 2. Age ≥ 18 years at the time of informed consent 3. Male 4. History of any grade 3 or higher peripheral neuropathy after receiving standard dose cisplatin completed more than 1 year but within the last 5 years 5. Long-term persistence (\> 6 months) of grade 2 or higher peripheral neuropathy after completion of a cisplatin containing regimen. 6. Patient understands the nature of the study and provides written informed consent Inclusion Criteria---Control Group 1. Diagnosis of testicular cancer 2. Age ≥ 18 years 3. Male 4. No history of neurotoxicity (grade 0-1) after completion of a standard cisplatin-containing chemotherapy regimen completed more than 1 year but within the last 5 years 5. Matched to a specified subject with neurotoxicity based on age (within 10 years), chemotherapy regimen or total cisplatin dosage 6. Patient understands the nature of the study and provides informed consent Exclusion Criteria (Both groups) 1. Treatment with other severely neurotoxic chemotherapy prior to or concomitantly with cisplatin. 2. Presence of peripheral neuropathy prior to cisplatin therapy 3. Poorly controlled or insulin-dependent diabetes or other conditions likely to predispose neurotoxicity (alcoholism, Charcot-Marie-Tooth disease)
References
Publications (0)
Data not yet available